

HOPE™ Autism Products Launched in Australia as TGA Adds to Special Access Scheme

27 October 2020

- **HOPE 1™ and HOPE 2™ are now available for prescription to Australian patients through the Therapeutic Goods Administration (TGA) Special Access Scheme**
- **The HOPE™ cannabinoid medicines were developed to support the needs of patients with Autism Spectrum Disorder**
- **The Australian launch marks a further milestone towards the global commercialisation of HOPE™, which is already licensed in Pennsylvania and Louisiana USA and brings to five the number of product launches by Zelira in 2020**

Zelira Therapeutics Ltd (ASX: ZLD, OTCQB: ZLDAF) is pleased to announce that its proprietary cannabinoid medicines, HOPE 1™ and HOPE 2™, are now available by prescription to patients in Australia through the Therapeutic Goods Administration's (TGA) Special Access Scheme and via Authorised Prescribers. The HOPE™ range of products will be distributed nationally via Health House Holdings.

HOPE™ is part of Zelira's family of revenue generating medicinal cannabis formulations. The products consist of two pharmaceutical-grade proprietary formulations developed as pharmaceutical-grade products targeting Autism Spectrum Disorder (ASD) as a disease indication.

The HOPE™ (HOPE 1 & 2) products were launched under license to Ilera Healthcare in Pennsylvania in 2019 with the support of HOPE Grows for Autism, a leading autism advocacy group based in Pennsylvania. HOPE™ has since established itself as one of the top selling formulated medicinal cannabis products in Ilera Healthcare's portfolio. In August 2020, HOPE™ was launched under license in Louisiana in partnership with Advanced Biomedics LLC.

Dr. Richard Hopkins, Managing Director ex-USA said *"Following the success of the HOPE™ launches in Pennsylvania and Louisiana we are excited to make these products available to patients and physicians in Australia. This represents another key milestone in our commitment to bring the benefits of HOPE™ to patients in global markets. We believe HOPE™ can help support the unmet needs of the ASD community in Australia and look forward to working with all stakeholders to ensure they can access the benefits that medicinal cannabis can provide."*

This announcement has been approved and authorised for release by the board of Zelira Therapeutics Limited.

Richard Hopkins
CEO & Managing Director ex-USA

About Zelira Therapeutics (www.zeliratx.com)

Zelira Therapeutics Ltd is a leading global therapeutic medical cannabis company with access to the world's largest and fastest growing cannabis markets. Zelira owns a portfolio of proprietary revenue generating products and a pipeline of candidates undergoing clinical development that are positioned to enter global markets from 2020. The company is focused on developing branded cannabis products for the treatment of a variety of medical conditions including insomnia, autism and chronic non-cancer pain.

The Company has two proprietary formulations under the HOPE™ brand that are generating revenues in Pennsylvania and have been licensed in Louisiana with other states in the US expected to follow. Zelira has also developed Zenivol™ - a leading cannabinoid-based medicine for treatment of chronic insomnia. Zenivol has successfully completed the worlds first Phase 2a clinical trial for chronic insomnia where it was found to be a safe and effective treatment.

The Company conducts this work in partnership with world-leading researchers and organizations including Curtin University in Perth, Western Australia; the Telethon Kids Institute in Perth; the University of Western Australia, in Perth; St. Vincent's Hospital in Melbourne, Australia; and the Children's Hospital of Philadelphia (CHOP) in the United States.

Address

Level 26
140 St Georges Terrace
Perth WA 6000
AUSTRALIA
Tel: +61 8 6558 0886
Fax: +61 8 6316 3337
E: enquiries@zeliratx.com
W: www.zeliratx.com
ACN 103 782 378

Australia Contacts:

Dr. Richard Hopkins
Managing Director & CEO, Ex USA
+61 405 656 868
rhopkins@zeliratx.com
Level 26, 140 St Georges Terrace
Perth WA 6000
AUSTRALIA

U.S. Contacts:

Dr. Oludare Odumosu
Managing Director & CEO, USA
+1 909 855 0675
oodumosu@zeliratx.com
3553 West Chester Pike #110
Newtown Square PA 19073
UNITED STATES OF AMERICA

Tickers

Australia (ASX): ZLD
USA (OTCQB): ZLDAF

Monsoon Communications

Rudi Michelson
+61 3 9620 3333
rudim@monsoon.com

GVM Communications, Inc.

Gia Morón
+1 347 678 8079
gia@gvmcommsinc.com